INTRODUCTION: Azithromycin has been shown to reverse or halt the decline of forced expiratory volume in one s (FEV1) in patients with bronchiolitis obliterans (BOS) syndrome following lung transplant. The overall effect of azithromycin on the absolute values of FEV1 has not been compared between reported studies. We studied the effects of azithromycin on lung function in patients with post-lung transplant BOS syndrome. METHODS: A meta-analysis was performed using studies identified following an extensive database search. To be included, studies were published in English or French and explicitly reported percentage change in FEV1 or hazard ratios. RESULTS: A total of 10 studies were included in this review. One hundred and forty patients were evaluated after treatment with azithromycin for an average follow-up period of seven months. The mean percentage increase in FEV1 was 8.8 (CI 5.1-12.47) p < 0.001. The pooled hazard ratio was 0.25 (CI 0.06-0.56) p = 0.041 for a mean follow-up period of 2.9 yr. CONCLUSION: This study demonstrated a significant improvement in lung function in patients with BOS syndrome following lung transplant after seven months of treatment. It remains uncertain whether this improvement stays after seven months. We also found that patients on azithromycin were less likely to die from BOS syndrome compared with patients who were not on azithromycin.
INTRODUCTION:Azithromycin has been shown to reverse or halt the decline of forced expiratory volume in one s (FEV1) in patients with bronchiolitis obliterans (BOS) syndrome following lung transplant. The overall effect of azithromycin on the absolute values of FEV1 has not been compared between reported studies. We studied the effects of azithromycin on lung function in patients with post-lung transplant BOS syndrome. METHODS: A meta-analysis was performed using studies identified following an extensive database search. To be included, studies were published in English or French and explicitly reported percentage change in FEV1 or hazard ratios. RESULTS: A total of 10 studies were included in this review. One hundred and forty patients were evaluated after treatment with azithromycin for an average follow-up period of seven months. The mean percentage increase in FEV1 was 8.8 (CI 5.1-12.47) p < 0.001. The pooled hazard ratio was 0.25 (CI 0.06-0.56) p = 0.041 for a mean follow-up period of 2.9 yr. CONCLUSION: This study demonstrated a significant improvement in lung function in patients with BOS syndrome following lung transplant after seven months of treatment. It remains uncertain whether this improvement stays after seven months. We also found that patients on azithromycin were less likely to die from BOS syndrome compared with patients who were not on azithromycin.
Authors: Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen Journal: J Heart Lung Transplant Date: 2018-09-25 Impact factor: 10.247
Authors: Hemang Yadav; Steve G Peters; Karina A Keogh; William J Hogan; Patricia J Erwin; Colin P West; Cassie C Kennedy Journal: Biol Blood Marrow Transplant Date: 2016-08-26 Impact factor: 5.742
Authors: Carmen Gonzalez-Martinez; Katharina Kranzer; Grace McHugh; Elizabeth L Corbett; Hilda Mujuru; Mark P Nicol; Sarah Rowland-Jones; Andrea M Rehman; Tore J Gutteberg; Trond Flaegstad; Jon O Odland; Rashida A Ferrand Journal: Trials Date: 2017-12-28 Impact factor: 2.279
Authors: Vincent J Venditto; Dalia Haydar; Ahmed Abdel-Latif; John C Gensel; Michael I Anstead; Michelle G Pitts; Jarrod Creameans; Timothy J Kopper; Chi Peng; David J Feola Journal: Front Immunol Date: 2021-02-12 Impact factor: 8.786
Authors: C Tji-Joong Gan; Chris Ward; Gerard Meachery; James Laurence Lordan; Andrew J Fisher; Paul A Corris Journal: BMJ Open Respir Res Date: 2019-10-15